News
Follow recent peptide research updates, clinical trial signals, regulatory developments, and new study findings. Every Peptide summarizes the science in plain language and links back to primary sources where available.
A first-in-human NTSR1 imaging study points to a stranger future for radiopharmaceutical oncology: after hormone therapy, some prostate tumors may stop showing one familiar address and start showing another.
New conotoxin and spider-toxin studies point to a stranger future for pain medicine: not dulling pain broadly, but borrowing venom peptides to hit the electrical switches that make injured nerves fire.
A new PNAS study gives cell-penetrating peptides a more physical explanation: they may cross membranes by opening submillisecond pores, turning one of drug delivery's strangest tricks into something medicine can start to measure.
A new long-term paltusotine paper points to a strange category shift: some peptide-medicine breakthroughs may come from small pills that imitate peptide signals closely enough to replace injection routines.
New work on antimicrobial peptides points to a less glamorous but more decisive challenge: many peptides can punch holes in microbes, but the future belongs to systems that can predict, package, or localize that violence before it reaches human cells.
A small DOTATATE PRRT pilot study in progressive meningioma points to a larger cancer idea: some tumors may be treatable not because of where they started, but because they display an address a radioactive peptide can find.
A cluster of new preclinical peptide-drug conjugate studies points to a subtle shift in oncology: using familiar cancer receptors less as signaling switches and more as delivery portals for toxic payloads.
A small pediatric WT1 peptide vaccine trial in recurrent high-grade glioma missed its prespecified efficacy bar, but its immune-responder signal shows the hard question cancer vaccines still have to answer.
Icotrokinra, the FDA-approved oral peptide IL-23 receptor antagonist for plaque psoriasis, shows how peptide pills are moving from metabolic medicine into immunology.
Enlicitide, an oral macrocyclic peptide PCSK9 inhibitor, is turning cholesterol treatment into a test case for whether complex peptides can become everyday pills.
A preclinical teriparatide delivery study shows why the next long-acting peptide problem may be timing: some medicines work because the body sees pulses, not a constant drip.
A new macrocyclic peptide inhibitor aimed at pathological mitochondrial fission shows why cyclic peptides are becoming serious tools for protein-protein interaction drug design, not just niche chemistry.
New review, real-world, and animal data point to a less glamorous GLP‑1 question: not just whether obesity drugs work, but what repeated interruption, restart, and weight cycling could mean for long-term care.
Lariocidin is a newly described lasso peptide antibiotic that targets the bacterial ribosome in an unusual way, offering a reminder that peptide drugs are not only about hormones and weight loss.
A phase 1 KRAS peptide vaccine study shows why the next cancer-vaccine story may be less about picking an antigen and more about getting peptide signals to the right immune neighborhood.
A randomized Nature Medicine trial found that once-daily oral orforglipron helped people maintain more of their prior injectable GLP‑1 weight loss than placebo, pointing to a future where obesity treatment may include step-down maintenance strategies.
A randomized Lancet trial found that semaglutide plus therapy reduced heavy drinking days in people with alcohol use disorder and obesity, adding momentum to the idea that GLP‑1 drugs may affect reward behavior as well as weight.
A perioperative review argues that adverse effects from modern anti-obesity drugs can be mistaken for surgical or anesthesia complications, raising the bar for documentation, holds, and post-op restarts.
Researchers describe an enveloped virus-mimicking particle built from a simplified peptide plus tuned lipids, aiming for repeatable mRNA delivery to extrahepatic tissues like lung and spleen.
A new mouse study tests an exosome-based ‘biomimetic’ delivery idea for oral octreotide, hinting at a path beyond permeability enhancers but leaving big manufacturing and translation questions.
A large EHR-based preprint links semaglutide to lower rates of many neuropsychiatric diagnoses, with a ‘legacy’ signal that tracks maximum achieved dose more than weight loss.
A new observational study links GLP‑1 therapy to lower atrial fibrillation risk even when people do not lose weight, with the strongest signal reported for semaglutide.
A large real-world analysis links GLP‑1 plus SGLT2 combination therapy to lower rates of major liver and cardiovascular events in people with fatty liver disease and type 2 diabetes.
A new meta-analysis pools one-year results for vosoritide in children with achondroplasia, clarifying typical growth changes and the most common side effects.
A translational study links cholesterol-pathway inhibition (HMGCR/rosuvastatin) to lower acute GLP‑1 secretion in gut cells and mice, offering a plausible mechanism behind statins’ mild diabetes signal.
A mouse study engineers a sublingual nanovaccine that combines a gingipain antigenic peptide with CpG adjuvant inside a tetrahedral DNA scaffold and hydrogel, boosting salivary IgA and reducing periodontitis signs.
A new supportive-care commentary argues that as GLP‑1 drugs become common, cancer treatment teams may need routine nutrition and body-composition monitoring to avoid avoidable toxicity and dose changes.
A new mechanistic study shows SNAC, the absorption enhancer used in oral semaglutide, changes state with pH, salts, bile, and co-medications—conditions that may shape oral peptide consistency.
A large matched TriNetX study found prior GLP‑1 receptor agonist exposure was associated with fewer infections, less ICU care, and lower mortality after smaller thermal burns, but it cannot prove cause and effect.
A large register study using two comparator cohorts plus a self-controlled design found no increased rate of suicide or suicide attempts after starting GLP‑1 receptor agonists.
A rat study links the pancreatic hormone amylin to anxiety-like behavior, aggression, and sociability, with the central amygdala driving some effects in opposite directions in males and females.
In an in vitro rat brainstem-spinal cord setup, exendin-4 increased sympathetic nerve activity and depolarized key neurons, supporting a direct neural route for GLP-1 receptor agonist tachycardia.
A Nature Communications paper introduces CycloSEL, a mass spectrometry driven workflow that screens fully synthetic macrocycle libraries and reports an intracellular-target hit later optimized for permeability.
A 2026 paper retrains an all-atom diffusion model to generate accurate conformers for small cyclic peptides, including noncanonical amino acids and complex linkages, with a practical stereochemistry correction step.
In diabetic mice, a long-acting, fatty-acid–conjugated GLP-1 receptor agonist showed measurable effects when held under the tongue for about five minutes after the team tuned pH and excipients.
A bioRxiv preprint reports that a ‘random peptide mixture’ called FK20 can hit multiple fungal pathogens, disrupt biofilms, and show mouse efficacy, with a potentially lower resistance footprint.
A peptide-drug conjugate blocks PD‑L1 and LAG‑3 and conditionally releases a TLR7/8 agonist in tumors, aiming to repolarize macrophages and boost T-cell activity with less systemic toxicity.
A Journal of Medicinal Chemistry study uses yeast display to screen millions of disulfide-cyclized peptides and turns up low‑nanomolar inhibitors of human ACE2, backed by crystal structures.
A preprint suggests a simple chemical add-on can make a short LL-37 fragment more bacteria-killing, hinting at a reusable design rule for antimicrobial peptides.
In a small 2026 study of teens, blood levels of the peptide MOTS-c looked broadly similar in polycystic ovary syndrome and controls, and a tested mitochondrial variant was not seen in this group.
Researchers describe AMG 133, an antibody-peptide conjugate designed to combine GIP receptor antagonism with GLP-1 receptor agonism. It’s a design story about longer-acting multi-target biology, not a new approved therapy.
A mouse study reports an enzyme-responsive peptide that forms a bladder-local hydrogel depot to retain BCG longer, aiming to reduce washout and improve immune activation in non-muscle-invasive bladder cancer.
Researchers report a bicyclic peptide isomer (10‑Mansa) that selectively inhibits integrin αvβ6 and shows prolonged tumor enrichment in preclinical work, highlighting how 3D peptide shape can make or break targeting.
In osteoarthritic human chondrocytes, a BMP7-derived peptide (p[63–82]) shifted gene expression toward collagen assembly pathways and increased glycosaminoglycan content. A repair-flavored signal in human cells, not a joint therapy yet.
A study in humans and mice links lower ELABELA (ELA) levels to congenital heart disease and suggests a mitochondria-related mechanism in cardiac development. Promising as a biomarker lead, not a clinical test yet.
A network meta-analysis of phase 3 trials in adults without diabetes found all three major GLP-1 era weight-loss drugs reduced weight vs placebo, with higher-dose tirzepatide ranking highest on average.
A 2026 Advanced Science paper introduces INB3P, a machine-learning framework built for small peptide datasets. It predicts blood-brain barrier-penetrating motifs and offers interpretability tools, but still needs prospective validation.
An NPJ Biofilms & Microbiomes paper reports that a Streptococcus salivarius strain (SALI-10) produces phosphorylated lantibiotics (pLANs), can engraft into dysbiotic human-derived oral biofilms, suppress periopathogens, and shows a small first-in-human feasibility signal after 1 week of daily dosing. It’s early, but it’s a concrete example of peptide-like natural products paired with a ‘live’ delivery vehicle.
A Science Advances paper describes a bispecific ‘ImmTAAI’ molecule that binds a preproinsulin peptide–HLA complex on beta cells and delivers a PD‑1 agonist signal to suppress autoreactive T cells locally in human pancreas slice models. It’s early, but it’s an unusually concrete example of tissue-targeted immunomodulation in type 1 diabetes.
A 2026 umbrella review of prior meta-analyses reports GLP‑1 receptor agonists are associated with lower major adverse cardiovascular events and less ‘worsening heart failure’, plus a small improvement in 6‑minute walk distance. Mortality and heart-failure hospitalization results were not clearly improved, and evidence certainty ranged low to moderate.
Researchers report benzaldehyde-tagged cell-penetrating peptides can anchor to membrane proteins via reversible imine chemistry, helping cargo escape endosomes and reach the cytosol.
A new mechanistic study suggests LL-37 and HNP1 can form reversible aggregates that become more active on bacterial-like membranes while staying less toxic to human cells.
A 2026 PNAS paper reports a way to co-opt bacterial lipoprotein processing to biosynthesize lipidated macrocyclic peptides. It is a methods advance that could matter for lipopeptide discovery and tuning pharmacology.
A 2026 preclinical paper reports vasoactive intestinal peptide (VIP) can induce autophagy and cytotoxicity in renal cell carcinoma models, with a proposed SIRT3-dependent mechanism. Interesting biology, far from a therapy.
A 2026 PNAS paper reports constrained bicyclic peptides, inspired by the FI6v3 antibody HCDR3, that bind the conserved hemagglutinin stem and neutralize multiple influenza A subtypes in vitro.
A PNAS study reports that dermcidin, an antimicrobial peptide found in sweat, can bind influenza hemagglutinin, inhibit infection in vitro, and protect mice, with higher levels seen in asymptomatic humans.
In a small randomized crossover study, an intravenous infusion of LEAP2, an endogenous ghrelin receptor antagonist, reduced ad libitum food intake and lowered post-meal glucose in men with obesity.
An open-access meta-analysis reports higher odds of depression-related adverse events among GLP-1 receptor agonist users (OR 1.49), but between-study heterogeneity is extreme (I² ~99%), which limits how literally the pooled number should be taken.
A post hoc analysis of SURPASS-CVOT expands the endpoint list beyond classic MACE. In patients with type 2 diabetes and established CVD, tirzepatide was associated with fewer composite cardiovascular + kidney events than dulaglutide, with more GI side effects.
A Medicare target-trial emulation found similar thyroid-stimulating hormone (TSH) testing patterns after GLP-1 receptor agonist initiation versus SGLT-2 inhibitors in older adults on stable levothyroxine, despite weight loss often changing thyroid hormone requirements.
A systematic review and meta-analysis of 21 placebo-controlled trials in patients at increased cardiovascular risk found no clear difference in serious adverse events with tirzepatide, while gastrointestinal side effects remained more common. Mortality evidence was sparse.
In a mouse optic nerve crush model, the research peptide HDAP2 was associated with less mitochondrial loss in injured axons and higher retinal ganglion cell survival. Early preclinical neuroprotection, not a human result.
Lyngbyabellin Q, a marine cyanobacterial cyclic peptide, showed potent in vitro antimalarial activity but also signals actin-related cytotoxicity. A classic ‘potent but sharp’ natural-products starting point.
A medicinal-chemistry study suggests one residue, Aib, can sometimes ‘pre-organize’ macrocyclic peptides so they cross membranes more easily, improving oral exposure in mice. It is scaffold-dependent, not magic.
Researchers took an antimicrobial peptide, tightened it into a drug-like cyclic version (CYP9), and reported reduced lung-fibrosis signaling in preclinical models. Early, but a useful example of peptide engineering.
Pinealon and epitalon are short peptides with a real literature footprint, but the claim that an oral combo can reliably cut sleep needs while improving sleep quality is far ahead of strong human evidence.
A new randomized-trial meta-analysis (preprint) finds the ‘hard outcome’ signal in heart failure is not clean, but people with HFpEF and obesity report better symptoms and walk a bit farther on GLP‑1 drugs.
Researchers carved a tiny 12–amino acid fragment from a tooth-development protein and found it promoted ‘reparative dentine’ formation in a rat pulp-capping model. Early, but a nice example of protein-to-peptide simplification.
A living meta-analysis of placebo-controlled RCTs of semaglutide and tirzepatide lands near ‘no signal’ for acute pancreatitis. That’s reassuring, but rare-event uncertainty is exactly why this concern keeps coming back.
A meta-analysis comparing bariatric surgery with GLP‑1 drugs found the gap widened as follow-up got longer. The signal is strong, but still confounded by non-random treatment selection and real-world access differences.
A 2026 review of glucagon-like peptide therapies in short bowel syndrome puts the spotlight where patients live: side effects, monitoring, and the trade-offs that come with reducing dependence on IV nutrition.
A nationwide multicenter retrospective study from Japan (422 patients, 33 institutions) reports real‑world outcomes for 177Lu‑DOTATATE PRRT in advanced neuroendocrine neoplasms. Response and progression-free survival look broadly consistent with PRRT’s established role, with useful predictor breakdowns.
A 2026 mouse study reports that Ac2‑26, an Annexin A1–derived pro‑resolving peptide, reduced pain-like sensitivity and several joint damage readouts in collagenase-induced osteoarthritis. It’s preclinical—but it illustrates the logic of “resolution pharmacology.”
A 2026 *Virulence* paper reports that lachnospirin‑1 killed carbapenem-resistant *A. baumannii*, disrupted biofilms and persisters, and showed efficacy in mouse infection models. It is still preclinical, but it has the kind of signal package that can justify deeper development.
A 2026 Nature Chemistry paper suggests overall amino acid composition, more than specific motifs, can predict when peptides will aggregate on-resin during solid-phase synthesis. If it generalizes, it could turn synthesis guesswork into planning.
“Pentadecapeptide arginate” is being promoted online as a stabilized, enhanced BPC‑157 analog. The clean way to read the trend is as a verification exercise: what exactly is the compound, what evidence exists, and what would need to be true for the marketing claims to be more than adjectives.
A 2026 Biomaterials Materials paper tested QKCMP, a short VEGF-mimicking peptide, as a graft-embedded signal meant to accelerate endothelialization. The idea targets a real failure mode, but the evidence is still early and mostly in vitro.
A 2026 clinical perspectives paper pulls together what’s known (and unknown) about GLP‑1 drugs and fertility, contraception reliability, and pregnancy planning—plus what the drug labels actually say about washout and birth control.
A huge electronic health record analysis suggests GLP‑1 receptor agonists in type 1 diabetes may be linked to fewer major heart and kidney events without a clear increase in hospitalized DKA—a promising signal that still isn’t a randomized trial.
A new paper reports a rapid ‘single-shot’ automated method to chemically synthesize linear Hi1a, a disulfide-rich venom peptide studied for neuroprotection. It’s not a clinical result, but it can remove a real bottleneck.
A 2026 medRxiv preprint analyzed 410,198 Reddit posts about semaglutide and tirzepatide. GI symptoms dominated, but the real value is in seeing which experiences people choose to write about—and which clusters might deserve more explicit measurement.
A seed news post that establishes the research-tracker format for future peptide updates.
MOTS‑c is a real mitochondrial DNA-encoded peptide with intriguing metabolic effects in animal studies, but human evidence is still early and easy to overhype.
Peptides are real biology, but they are also a perfect vehicle for wishful thinking. This field guide helps separate molecule identity, evidence quality, and marketing.